Cargando…
The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: A retro-prospective comparative study in India
BACKGROUND: Monoclonal antibodies have gained attention in developing countries owing to its benefits portrayed by few clinical trials. However, no studies until now have been undergone in India. METHODS: A retro-prospective comparative observational study was conducted in symptomatic COVID19 patien...
Autores principales: | Joy, Aneesh Puthiyedath, Augustine, Anitha Theresa, Karattuthodi, Mohammed Salim, Parambil, Jaffer Chalil, Chandrasekher, Dilip, Danisha, P., Panakkal, Linu Mohan, Joshi, Madhav A., Azharul Haque, K.T., Mohammed Izudheen, Irshad K., Badaruddeen, Shadia, John, Riya Sara, Murali, Sarath, Thomas, Ardhra Rose, Sahla, Fathimath, Ahmed Unni, Shahir Ahmed KV., Ahmed, Raseel Omar, Cholamugath, Shinu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V. on behalf of INDIACLEN.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767937/ https://www.ncbi.nlm.nih.gov/pubmed/35071825 http://dx.doi.org/10.1016/j.cegh.2022.100967 |
Ejemplares similares
-
Casirivimab/Imdevimab: First Approval
por: Deeks, Emma D.
Publicado: (2021) -
Casirivimab and imdevimab for COVID-19
Publicado: (2022) -
Casirivimab/imdevimab: Lack of efficacy: case report
Publicado: (2022) -
Use of Casirivimab and Imdevimab for the Treatment of COVID-19
por: Liu, Ryan, et al.
Publicado: (2022) -
Casirivimab - Imdevimab in Covid 19 – Early Indian experience
por: Venkitakrishnan, Rajesh, et al.
Publicado: (2022)